EPA trials for primary prevention of bowel cancer & metastatic disease

Date: July 9, 2015
Time: All-day

Despite advances in treatment of bowel cancer, it remains the second most common cause of cancer death in the Western world. Use of drugs or nutritional supplements (chemoprevention) is an attractive strategy for prevention of bowel cancer in combination with other modalities such as population screening and endoscopic surveillance, particularly if the chemoprevention agent is safe, well tolerated and cost effective. This webinar describes existing evidence that omega-3 fatty acids have activity against bowel cancer. Recent completed and ongoing clinical trials of EPA for primary prevention of bowel cancer and prevention of metastatic disease are described. Current thinking about how omega-3 fatty acids might work against bowel cancer are also explained.

Print Friendly, PDF & Email

Professor Mark Hull

About Professor Mark Hull

Mark Hull PhD FRCP is a Clinician Scientist and Consultant Gastroenterologist with a research interest in the molecular basis of colorectal carcinogenesis and colorectal cancer prevention. He trained in Biochemistry at the University of Cambridge and Medicine at the University of Oxford. His PhD studies investigated the cell biology of gastric ulcer healing at the University of Nottingham. He has previously been awarded MRC Clinician Scientist and Senior Clinical Fellowships. He has been awarded the Linacre Medal by the Royal College of Physicians of London. Mark is Professor of Molecular Gastroenterology at the University of Leeds and a Consultant Gastroenterologist at Leeds Teaching Hospitals NHS Trust. His research interests focus on bowel cancer prevention, particularly the use of omega-3 fatty acids (so-called chemoprevention) for prevention and treatment of bowel cancer.